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Introduction
Juvenile dermatomyositis (JDM) is a rare chronic, auto-
immune vasculopathic disease with mainly muscle and
skin involvement. The incidence described in USA is
2.5-4.1 cases per million children; the disease is slightly
more common in girls. Recent studies describe that two
third of the patients followed a chronic disease course,
whereas only one third showed monocyclic disease
course.
Objectives
Assess disease characteristics and outcome of JDM in
Western Switzerland.
Methods
Retrospective review of charts from 1997-2010 in pedia-
tric rheumatology in Lausanne and Geneva.
Results
W ed e s c r i b eap o p u l a t i o no f1 3p a t i e n t sp r e s e n t i n ga
JDM followed in the two centers of pediatric rheuma-
tology in western Switzerland from 1997-2010. The
incidence of JDM in our region is similar to other stu-
dies (3.5 cases per million children). The mean age of
onset was 6 years (3 - 10 years); no gender predomi-
nance was found. The mean follow up was 6 years (3
months - 14 years). All patients presented a rash (Got-
tron’s rash, heliotrope rash or extensor surface rash, in
one patient only during follow-up), muscle weakness
(assessed by CMAS and or Kendall score) and evidence
of myositis (biopsy, elevated muscle enzymes, magnetic
resonance imaging or by electromyography). The med-
ian delay of diagnosis was 2 months, 3 patients had a
longer delay because of misleading symptoms. Follow
up of more than one year is available in 12 patients. In
comparison with other studies, evolution was predomi-
nantly monocyclic (50% of all cases showed remission
within 2 years after diagnosis). All patients were trea-
ted by corticosteroids and Methotrexate. If skin mani-
festation predominated, Hydroxychloroquin was added
(40% of all cases). In the six other patients with
chronic polycyclic, intermittent and chronic disease
course, multiple treatment changes were required
including Ciclosporine, Azathioprin, immunoglobu-
lines, Infliximab, Adalimumab, Rituximab. Only one
patient had pulmonary complications (interstitial pneu-
monia) and 1 patient still presents functional impair-
ment. Calcinosis was present in 3 patients (23%). All
patients showed at one point impregnation of corticos-
teroid treatment. One patient presented pancreatitis
and fungal infection related to treatment. Growth
impairment was seen in 3 patients (23%).
Conclusion
In our study we show a better outcome compared to
other recent reports. This could be due to early diagno-
sis and rapid treatment onset or less severe presentation
of the disease in our patients. Early referral to a refer-
ence center and rapid treatment with corticosteroids
combined with Methotrexate may improve the outcome.
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